Interleukin-32 is a species-specific cytokine that plays an important role in inflammation, cancer, and other diseases; however, its role in reproductive and pregnancy-related diseases remains unknown. This study aimed to investigate the role of interleukin-32 in reproductive and pregnancy-related diseases. Placental tissues from patients with pregnancy-induced hypertension, healthy pregnant women, and trophoblast lines were analysed. Interleukin-32 expression was quantified via polymerase chain reaction and immunohistochemistry, and functional assays were performed after interleukin-32 modulation. Interleukin-32 was identified only in placental mammals, such as Carnivora, Cetartiodactyla, Chiroptera, Dermoptera, Lagomorpha, Perissodactyla, and Primates via bioinformatics. Immunohistochemistry and polymerase chain reaction revealed that interleukin-32 was highly expressed in human placental villi, poorly expressed in decidua and endometrial tissues, and was not detected in mouse tissues. Second, interleukin-32 upregulates miR-205 expression by increasing DROSHA expression, and miR-205 promotes interleukin-32 expression by targeting its promoter region. Interleukin-32 and miR-205 significantly enhanced the invasion ability of HTR8/SVneo cells (a trophoblast cell line) and the tube formation ability of human umbilical vein endothelial cells. Through quantitative reverse transcription polymerase chain reaction and western blotting, the interleukin-32/miR-205 loop increased MMP2 and MMP9 expression in HTR-8/SVneo cells via the nuclear factor kappa B signalling pathway. Finally, using quantitative reverse transcription polymerase chain reaction, interleukin-32 and miR-205 expression levels were significantly lower in the placentas of patients with pregnancy-induced hypertension than in women with normal pregnancies. In conclusion, interleukin-32 regulates trophoblast invasion through the miR-205-nuclear factor kappa B-MMP2/9 pathway, which is involved in pregnancy-induced hypertension.
Small cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare, aggressive cervical cancer with poor prognosis. This study explored molecular drivers of SCNECC progression and identified potential therapeutic targets. Proteomic analysis was conducted to identify differentially expressed proteins (DEPs) in SCNECC. Subsequent GO and KEGG enrichment analyses were performed to delineate key DEPs. Functional assays, including CCK-8, colony formation, cell cycle, and apoptosis assays, were conducted to assess the roles of target genes. Expression levels of target genes were validated using qRT-PCR, western blot, and immunohistochemistry (IHC). Proteomic profiling revealed 2333 DEPs in SCNECC, comprising 2168 upregulated and 165 downregulated proteins. GO and KEGG analyses revealed that the upregulated DEPs were predominantly enriched in processes occurring within the cell nucleus, such as DNA replication, reflecting heightened proliferative activity in SCNECC. IHC confirmed FEN1 overexpression. Functional assays showed that FEN1 knockdown suppressed cell viability, colony formation, and cell cycle, promoted apoptosis, and impeded tumor growth in mice. SC13, a FEN1 inhibitor, also had similar effects. Furthermore, silencing FEN1 markedly reduced PIK3CA, PCNA, and BCL-2 levels, while elevating Caspase-9 expression. CONCLUSION: FEN1 overexpression fuels SCNECC progression via PCNA regulation, positioning FEN1 as a promising SCNECC therapeutic target.
Context: Cervical cancer (CC) is one of the leading cancers threatening women’s health worldwide. Folate is essential for one-carbon metabolism, influencing DNA synthesis and methylation. However, the role of folate status in cervical carcinogenesis is not fully understood. Objective: To explore the association between folate deficiency and CC risk in women, and the association between folate supplementation and the regression of cervical intraepithelial neoplasia (CIN). Data Sources: We conducted a comprehensive literature search in PubMed and Ovid databases with no initial restrictions on publication dates initially conducted on June 1, 2023, and updated on January 30, 2025. Mendelian randomization data were obtained from the IEU Open GWAS Project database (https://gwas.mrcieu.ac.uk/). Data Extraction: Two of the authors independently extracted data using a standardized method and protocol. Data Analysis: Twenty-five studies with 14 304 participants were included. The lowest quartile of dietary folate intake (odds ratio [OR]: 1.36; 95% CI: 1.18, 1.58), serum folate (OR: 1.54; 95% CI: 1.18, 2.01), and red blood cell (RBC) folate (OR: 1.43; 95% CI: 1.07, 1.93) were associated with a higher CIN and/or CC risk. Dose–response meta-analysis indicated that an additional 240–280.5 μg/day of folate supplementation was associated with a reduction in CIN and/or CC risk by up to 26%. Each 5-nmol/L increase in serum folate and 50-nmol/L increase in RBC folate were associated with 21% and 5% risk reductions, respectively. Folate supplementation showed a significant association with CIN regression (OR: 1.23; 95% CI: 0.88, 1.72). Mendelian randomization supported a reduced CC risk linked to folate intake (OR: 1.000252; 95% CI: 1.000036, 1.000468). Conclusion: Our findings suggest that an additional 240–280.5 μg/day of folate supplementation, along with higher serum and RBC folate concentrations, may be associated with reduced CIN and/or CC risk, highlighting the importance of folate in CC prevention. Systematic Review Registration: PROSPERO registration no.: CRD42019123443.